Press Releases

Press Releases

Jul 07, 2020
Funding supports late-stage clinical development, including pivotal Phase 3 clinical trial to support licensure OWS award funds large-scale manufacturing of NVX-CoV2373, including production of 100 million doses starting in late 2020 GAITHERSBURG, Md....
Jul 02, 2020
Frank Czworka appointed SVP, Global Sales Brian Webb promoted to SVP, Manufacturing GAITHERSBURG, Md. , July 02, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the...
Jun 29, 2020
GAITHERSBURG, Md. , June 29, 2020 (GLOBE NEWSWIRE) -- Novavax , Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Ben Machielse as Executive Vice President, CMC, with responsibility for...
Jun 24, 2020
GAITHERSBURG, Md. , June 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino , Senior Vice President, Chief Business Officer and Chief Financial...
Jun 17, 2020
Dr. Filip Dubovsky appointed SVP, Chief Medical Officer Silvia Taylor appointed SVP, Investor Relations and Corporate Affairs GAITHERSBURG, Md. , June 17, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious...
Jun 16, 2020
GAITHERSBURG, Md. , June 16, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has appointed David Mott as an independent director to its Board of Directors. Mr....
Jun 15, 2020
GAITHERSBURG, Md. , June 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has entered into an agreement to sell Series A Convertible preferred stock, convertible...
Jun 04, 2020
$60 million funding for manufacturing of NVX-CoV2373 10 million doses to be delivered to DoD in 2020 GAITHERSBURG, Md. , June 04, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Displaying 21 - 30 of 192